BPC
CAPR icon

Bryce Point Capital’s Capricor Therapeutics CAPR Stock Holding History

Bryce Point Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,709
Closed -$313K – 225
2024
Q4 		$313K Buy
+22,709
New +$398K 0.09% 391

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bryce Point Capital's CAPR Position: Q1 2025 in Review

Bryce Point Capital sold out of Capricor Therapeutics (CAPR) in Q1 2025, closing a stake of 22,709 shares — an estimated $313K sold.

Bryce Point Capital first reported a position in CAPR in Q4 2024 and held it in 1 quarter. The position peaked at $313K in Q4 2024. 120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

  • Bryce Point Capital reported no remaining Capricor Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 22,709 Capricor Therapeutics shares in Q1 2025, an estimated $313K.
  • Bryce Point Capital first reported a position in Capricor Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Capricor Therapeutics position peaked at $313K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.